HER-2 PROTEIN OVEREXPRESSION
Clinical trials for HER-2 PROTEIN OVEREXPRESSION explained in plain language.
Never miss a new study
Get alerted when new HER-2 PROTEIN OVEREXPRESSION trials appear
Sign up with your email to follow new studies for HER-2 PROTEIN OVEREXPRESSION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to keep HER2+ esophageal cancer from coming back
Disease control OngoingThis study is for people with HER2-positive esophageal or gastroesophageal junction cancer who have already completed chemoradiation and surgery. The goal is to see if adding a year of treatment with trastuzumab deruxtecan (Enhertu) plus nivolumab is safe and helps prevent the ca…
Matched conditions: HER-2 PROTEIN OVEREXPRESSION
Phase: PHASE2 • Sponsor: Brown University • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC
-
New imaging agent lights up HER2-Positive breast cancer in early trial
Diagnosis OngoingThis early-phase study tests whether a new radioactive imaging agent, 89Zr-ss-pertuzumab, is safe for people with HER2-positive breast cancer. The agent is designed to attach to HER2 proteins on cancer cells, making them visible on scans. About 60 participants will receive the ag…
Matched conditions: HER-2 PROTEIN OVEREXPRESSION
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Diagnosis
Last updated Jun 02, 2026 11:40 UTC